**Name of Journal: *World Journal of Hepatology***

**ESPS Manuscript NO: 21285**

**Manuscript Type: Original Article**

***Retrospective Study***

**Vitamin E** **reduces liver stiffness in nonalcoholic fatty liver disease**

Fukui A *et al.* Vitamin E reduces NAFLD liver stiffness

**Aiko Fukui, Naoto Kawabe, Senju Hashimoto, Michihito Murao, Takuji Nakano, Hiroaki Shimazaki, Toshiki Kan, Kazunori Nakaoka, Masashi Ohki, Yuka Takagawa, Tomoki Takamura, Hiroyuki Kamei, Kentaro Yoshioka**

**Aiko Fukui**, **Hiroyuki Kamei**, Department of Clinical Pharmacy Practice and Health Care Management, Faculty of Pharmacy, Meijo University, Aichi 468-8503, Japan

**Aiko Fukui**, **Naoto Kawabe, Senju Hashimoto, Michihito Murao, Takuji Nakano, Hiroaki Shimazaki, Toshiki Kan, Kazunori Nakaoka, Masashi Ohki, Yuka Takagawa, Tomoki Takamura, Kentaro Yoshioka,** Department of Liver, Biliary Tract and Pancreas Diseases, Fujita Health University, Aichi 470-1192, Japan

**Author contributions:** Fukui A proposed the study; Kawabe N, Hashimoto S, Murao M, Nakano T, Shimazaki H, Kan T, Nakaoka M, Ohki M, Takagawa Y, Takamura T and Yoshioka K performed the research; Fukui A collected and analyzed the data; Fukui A, Kawabe N, Kamei H and Yoshioka K contributed to the design and interpretation of the study and to further drafts; Yoshioka K is the guarantor; all authors contributed equally to this work.

**Institutional review board statement:** This study conformed to the Japanese Good Clinical Practice and the Declaration of Helsinki, and was reviewed and approved by the Ethics Committee of the Fujita Health University Hospital (IRB number: 14-020).

**Informed consent statement:** Each patient gave a written informed consent.

**Conflict-of-interest statement:** We have no financial relationships to disclose.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Correspondence to:** **Kentaro Yoshioka, MD**, Department of Liver, Biliary Tract and Pancreas Diseases, Fujita Health University, 1-98 Dengakugakubo, Kutsukake, Toyoake, Aichi 470-1192, Japan. [kyoshiok@fujita-hu.ac.jp](mailto:kyoshiok@fujita-hu.ac.jp)

**Telephone:** +81-562-932324

**Fax:** +81-562-938601

**Received:** July 3, 2015

**Peer-review started:** July 6, 2015

**First decision:** September 8, 2015

**Revised:** September 20, 2015

**Accepted:** November 10, 2015

**Article in press:**

**Published online:**

**Abstract**

**AIM:** To evaluate the efficacy of vitamin E treatment on liver stiffness in nonalcoholic fatty liver disease (NAFLD).

**METHODS:** Thirty-eight NAFLD patients were administered vitamin E for > 1 year. The doses of vitamin E were 150, 300, or 600 mg; three times per day after each meal. Responses were assessed by liver enzyme levels [aspartate aminotransferase (AST), alanine aminotranferease (ALT), and [γ-glutamyl transpeptidase](http://xueshu.baidu.com/s?wd=%CE%B3-glutamyl%20transpeptidase%20%28%CE%B3-GTP%29&tn=SE_baiduxueshu_c1gjeupa&ie=utf-8) (γ-GTP)], noninvasive scoring systems of hepatic fibrosis (FIB-4 index and APRI), and liver stiffness (velocity of shear wave: Vs) measured by acoustic radiation force impulse elastography. Vs measurements were performed at baseline and 12 mo after baseline. The patients were genotyped for the patatin-like phospholipase domain containing 3 (*PNPLA3*) polymorphisms and then divided into either the CC/CG or GG group to examine each group’s responses to vitamin E treatment.

**RESULTS:** We found marked differences in the platelet count, serum albumin levels, alkaline phosphatase levels, FIB-4 index, APRI, and Vs at baseline depending on the *PNPLA3* polymorphism. AST, ALT, and γ-GTP levels (all *P* < 0.001); FIB-4 index (*P* = 0.035); APRI (*P* < 0.001); and Vs (*P* < 0.001) significantly decreased from baseline to 12 mo in the analysis of all patients. In the subset analyses of *PNPLA3* genotypes, AST levels (*P* = 0.011), ALT levels (*P* < 0.001), γ-GTP levels (*P* = 0.005), APRI (*P* = 0.036), and Vs (*P* = 0.029) in genotype GG patients significantly improved, and AST and ALT levels (both *P* < 0.001), γ-GTP levels (*P* = 0.003), FIB-4 index (*P* = 0.017), and APRI (*P* < 0.001) in genotype CC/CG patients.

**CONCLUSION:** One year of vitamin E treatment improved noninvasive fibrosis scores and liver stiffness in NAFLD patients. The responses were similar between different *PNPLA3* genotypes.

**Key words:** Vitamin E; Nonalcoholic fatty liver disease; Acoustic radiation force impulse; Patatin-like phospholipase domain containing 3; Velocity of shear wave

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Responses to vitamin E treatment in nonalcoholic fatty liver disease patients were assessed by noninvasive scoring systems of hepatic fibrosis, and liver stiffness (velocity of shear wave) was measured by acoustic radiation force impulse elastography. Vitamin E treatment for 1 year improved not only liver enzyme levels but also noninvasive fibrosis scores and liver stiffness. Subsequently, the patients were divided into two groups according to patatin-like phospholipase domain containing 3 (*PNPLA3*) genotype (CC/CG or GG) to examine whether either group responded differently to the treatment. The responses were similar between different *PNPLA3* genotypes.

Fukui A, Kawabe N, Hashimoto S, Murao M, Nakano T, Shimazaki H, Kan T, Nakaoka K, Ohki M, Takagawa Y, Takamura T, Kamei H, Yoshioka K. Vitamin E reduces liver stiffness in nonalcoholic fatty liver disease. *World J Hepatol* 2015; In press

**INTRODUCTION**

Nonalcoholic fatty liver disease (NAFLD) is a common liver disease[1], and nonalcoholic steatohepatitis (NASH) characterized by steatosis with necroinflammation and eventual fibrosis[2] can lead to end-stage cirrhosis and hepatocellular carcinoma[3].

Although there are no generally approved treatments for NASH, several treatment options have demonstrated efficacy in various clinical trials. Statins[4-7], insulin sensitizers such as thiazolidinediones[8,9], and metformin[10] are effective for the treatment of NAFLD[11]. Oxidative stress plays a central role in the transition from simple steatosis to NASH[12]. An effective therapeutic strategy is to target reduction in oxidative stress using, for example, administration of vitamin E. A recent trial has provided substantial evidence for the previously suggested efficacy of vitamin E in inducing histological improvement of NASH[13].

Evaluation of liver fibrosis is essential in chronic liver diseases because the prognosis of the diseases and the treatment decisions often depend on fibrosis. Liver biopsy is still considered the gold standard for liver fibrosis assessment, despite being an invasive method and not completely risk free[14]. In recent years, noninvasive methods, aimed at replacing liver biopsy, have been developed for the evaluation of liver fibrosis. Development of noninvasive tools will enable monitoring of the disease progression and response to therapy. Velocity of shear wave (Vs) measured by acoustic radiation force impulse (ARFI) has been reported to be a good method for assessing the stage of liver fibrosis[15,16]. Vs has been reported to be useful in diagnosing NAFLD[17-19].

The single-nucleotide polymorphism rs738409 (C > G) in the patatin-like phospholipase domain containing 3 (*PNPLA3*) was strongly associated with increased hepatic fat levels and with hepatic inflammation in NAFLD patients[20-23]. However, the effect of the *PNPLA3* polymorphisms on the response to treatment has not been reported.

The aims of this study were to evaluate the efficacy of vitamin E treatment for NAFLD by noninvasive methods and to assess the association between the treatment response and the *PNPLA3* polymorphism present.

**MATERIALS AND METHODS**

***Patients***

Vitamin E was administered for > 1 year to 38 patients with NAFLD as treatments for atherosclerosis, diabetic retinopathy, or prevention of lipid peroxidation from January 2011 to July 2015. The patients showed no improvement in aminotransferase levels following lifestyle modification such as dietary modification and exercise before beginning vitamin E treatment. Their clinical data were retrospectively studied (Table 1). The diagnosis of NAFLD was confirmed by liver biopsy in 10 patients, by ultrasonic examination in 23 patients, and by presence of cirrhosis with no obvious etiology and with metabolic risk factors such as obesity and metabolic syndrome in 5 patients[11]. None of the patients consumed > 40 g of alcohol per day. The patients who increased the dose of or started other medicines for NAFLD, such as pioglitazone, metformin, ursodeoxycholic acid, statins, ezetimibe, or angiotensin 2 receptor antagonist, during the study period were excluded from this study.

***Vitamin E administration***

The total doses of 150, 300 or 600 mg vitamin E were orally given into 3 administrations per day after each meal for > 1 year: 150 mg for 2 patients, 300 mg for 4 patients, or 600 mg for 32 patients (100 mg is equivalent to 100 IU; Eisai Pharmaceutical Co., Tokyo, Japan). In the American Association for the Study of Liver Diseases (AASLD) practice guideline, vitamin E was recommended to be administered to nondiabetic adults with biopsy-proven NASH at a daily dose of 800 IU[11]. However, the dosage of vitamin E accepted by health insurance in Japan is 150-300 mg for atherosclerosis or diabetic retinopathy, and 300-600 mg for prevention of lipid peroxidation.

***Laboratory data and noninvasive scoring systems***

Laboratory data were collected at three time points: at baseline (beginning of vitamin E administration), 6 and 12 mo after baseline. Two noninvasive scoring systems of hepatic fibrosis, the fibrosis-4 (FIB-4) index and the aspartate aminotransferase-to-platelet index (APRI), were calculated from the measurements using the originally reported formulas[24,25]. The APRI formula was AST level (U/L) × AST (upper limit of normal; U/L)/platelet (109/L) × 100 and the FIB-4 score formula was age (years) × AST level (U/L)/platelet (109/L) × √ALT (U/L). These noninvasive scoring systems were used at each of the time points.

***Vs measurement by ARFI elastography***

Vs measurement by ARFI elastography was performed at baseline and 12 mo after baseline using a Siemens ACUSON S2000 (Siemens Medical Systems Co., Ltd., Tokyo, Japan). The examination was performed on the right lobe of the liver. A measurement depth of 2-3 cm below the liver capsule was chosen. Ten successful acquisitions at different locations were performed on each patient, and the results are expressed as median values in m/s. Vs is considered to be proportional to the square root of tissue elasticity. Histological improvement was not examined because sequential liver biopsy was not performed.

***PNPLA3 rs738409 genotyping***

Genomic DNA was extracted from whole blood samples using QIA amp DNA Mini Kits (Qiagen, Tokyo, Japan), according to the manufacturer’s protocol. The rs738409 *PNPLA3* SNP was genotyped using TaqMan predesigned SNP genotyping assays (Applied Biosystems, Tokyo, Japan), according to the manufacturer’s protocol. The patients were divided into two groups by *PNPLA3* genotype (CC/CG *vs* GG) to examine the different responses to vitamin E in each group (Figure 1).

***Statistical analysis***

Differences in the two groups in terms of clinical characteristics and laboratory values at baseline were analyzed using either the χ2 test or the Mann-Whitney *U* test. Differences between the laboratory values obtained at three time points were analyzed using the Freedman test. Differences between the laboratory values obtained at two time points were analyzed using Wilcoxon’s signed-rank test with Bonferroni’s correction. Differences were judged as significant if the *P* value was < 0.05 (two-tailed). All statistical analyses were conducted using SPSS software (SPSS Statistics Version 22; IBM Co., Armonk, NY).

**RESULTS**

***Baseline characteristics***

Seven obese patients included in this study exceeded their ideal body weight (body mass index was > 32 kg/m2), and 39.5% of patients had type 2 diabetes (Table 1). Platelet counts and serum albumin levels in the GG group were significantly lower than those in the CC/CG group (*P* = 0.046, and *P* = 0.032, respectively). Alkaline phosphatase levels, FIB-4 index, APRI, and Vs in the GG group were significantly higher than those in the CC/CG group (*P* = 0.032, *P* = 0.006, *P* = 0.014, and *P* = 0.010, respectively).

***Body weight change***

Body weight in all patients did not change from baseline to 12 mo (68.2 ± 14.9 kg and 72.4 ± 16.8 kg, respectively). There were no patients who achieved > 7% weight loss during study periods.

***Effect of vitamin E on serum AST, ALT, and γ-GTP levels***

Serum AST, ALT and γ-GTP levels in all patients significantly decreased from baseline to 6 mo (*P* < 0.001, *P* < 0.001, and *P* = 0.019, respectively) and 12 mo (*P* < 0.001, *P* < 0.001, and *P* < 0.001, respectively). Those in the CC/CG group also significantly decreased from baseline to 6 mo (*P* = 0.004, *P* = 0.022, and *P* = 0.047, respectively) and 12 mo (*P* < 0.001, *P* < 0.001, and *P* = 0.003, respectively). Serum AST and ALT levels in the GG group significantly decreased from baseline to 6 mo (*P* = 0.045, and *P* = 0.004, respectively) and 12 mo (*P* = 0.011, and *P* < 0.001, respectively), and serum γ-GTP levels in the GG group significantly decreased from baseline to 12 mo (*P* = 0.005) (Figure 2).

***Effect of vitamin E on the FIB-4 index***

The FIB-4 index in all patients significantly decreased from baseline to 6 and 12 mo (*P* = 0.015 and *P* = 0.035, respectively). FIB-4 index in the CC/CG group also significantly decreased from baseline to 6 and 12 mo (*P* = 0.014 and *P* = 0.017, respectively). On the other hand, the FIB-4 index did not change in the GG group (Figure 3A).

***Effect of vitamin E on APRI***

APRI in all patients significantly decreased from baseline to 6 and 12 mo (*P* < 0.001 and *P* < 0.001, respectively). APRI in the CC/CG group significantly decreased from baseline to 6 and 12 mo (*P* = 0.004 and *P* < 0.001, respectively). APRI in the GG group also significantly decreased from baseline to 6 and 12 mo (*P* = 0.028 and *P* = 0.036, respectively; Figure 3B).

***Effect of vitamin E on Vs***

Vs in all patients decreased from baseline to 12 mo (*P* = 0.005). Vs in the GG group also decreased from baseline to 12 mo (*P* = 0.029), and Vs in the CC/CG group also tended to decrease; however, the decrease was not significant (Figure 4).

**DISCUSSION**

The present study showed that a 1-year treatment of vitamin E improved not only laboratory values but also the noninvasive scores related to hepatic fibrosis and liver stiffness in NAFLD patients. The treatment responses are similar between different *PNPLA3* genotypes.

In general, lifestyle modification should be the first line of treatment in patients with NAFLD, and it was reported that weight reduction greater than 7% achieved through lifestyle intervention improves aminotransferase levels and liver histology[26]. Because the weight of patients in the present study did not change during the study period, it was assumed that the outcomes were not affected by weight loss.

Recently, a large, multicenter randomized controlled trial was conducted by the NASH Clinical Research Network to evaluate the efficacy of vitamin E treatment for amelioration of NASH in adults [pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis (PIVENS)][13]. This trial reported that serum AST, ALT, and γ-GTP levels in the vitamin E group decreased compared with the placebo group and that the changes occurred in the first 24 wk and were sustained throughout the study period. In our study, the changes occurred 6 mo after baseline, which was consistent with the PIVENS study.

Liver biopsy is regarded as the gold standard in the assessment of patients with NAFLD/NASH. However, liver biopsy is an invasive procedure with potential complications, and sampling error can result in substantial misdiagnosis and staging inaccuracies. Recently, several indices have been developed for noninvasive tests that help to diagnose advanced liver disease. The FIB-4 index and APRI can easily be used at the bedside or in an outpatient setting because of the simple calculation of only a few laboratory values. In our study, the FIB-4 index and APRI markedly decreased from baseline to 6 and 12 mo. These findings may indicate that the administration of vitamin E improved liver fibrosis. However, since these scoring systems are calculated using ALT, the reduction of the score may be attributed to the reduction of hepatic inflammation.

In recent years, several studies have reported the usefulness of ARFI elastography for the assessment of liver stiffness and a positive correlation between Vs and biopsy-proven fibrosis stage in patients with NAFLD[17-19]. ARFI elastography has mainly been used in diagnosis[27] and there are no reports of it being used for assessment of the efficacy of vitamin E treatment in NAFLD patients. In our study, Vs markedly decreased from baseline to 12 mo. In the subset analysis of 32 patients without six patients with daily doses of 150 mg and 300 mg of vitamin E, Vs markedly decreased from baseline to 12 mo (*P* = 0.004). The reduction of Vs probably indicates a reduction in liver fibrosis. The PIVENS trial reported that the vitamin E group had a reduction in steatosis, lobular inflammation, and activity score, whereas fibrosis scores did not markedly improve[13]. The fact that ARFI revealed a reduction in liver stiffness in the present study despite no demonstration of a significant reduction in fibrosis by liver biopsies in the PIVENS trial may indicate that ARFI is more sensitive than liver biopsies for detecting the reduction of fibrosis. There may be possibility that the reduction of Vs is attributed to factors other than reduction of fibrosis.

Yoneda *et al*[17] reported that Vs differed between groups with different inflammatory activity in 54 patients. Fierbinteanu *et al*[19] reported that Vs had a positive correlation with inflammation in 64 patients. On the other hand, Palmeri *et al*[18] reported that Vs was not associated with inflammation scores in 172 patients. Thus, the association between Vs and inflammation is still unclear, and further studies are required in this field.

The association between the *PNPLA3* polymorphisms with not only fatty liver and triglyceride content, but also with inflammation and fibrosis in NAFLD has been reported[22,28,29]. A meta-analysis reported that GG homozygous had a 3.24-fold greater risk of higher necroinflammatory scores and a 3.2-fold greater risk of developing fibrosis than CC homozygous[29]. In the present study, there were some differences at baseline depending on the *PNPLA3* polymorphism. The platelet counts and serum albumin levels were lower, and alkaline phosphatase levels, the FIB-4 index, APRI, and Vs were higher in GG patients than in CC/CG patients. Our results were consistent with previous reports.

In the subset analyses of *PNPLA3* genotypes, AST and ALT levels, APRI, and Vs in genotype GG patients and AST, ALT, and γ-GTP levels, FIB-4 index, and APRI in genotype CC/CG patients improved following vitamin E treatment. Vitamin E treatment for 1 year improved not only liver enzyme levels but also noninvasive fibrosis scores and liver stiffness in NAFLD patients. The responses are similar between different *PNPLA3* genotypes.

The most effective dosage of vitamin E is unclear. In the PIVENS trial, 800 IU of vitamin E was administered per day. However, a previous study reported that patients with vascular disease or diabetes mellitus who received long-term supplementation with vitamin E (400 IU per day) had a higher risk of heart failure and hospitalization for heart failure[30]. These results may suggest that we have to avoid vitamin E treatment for patients with vascular disease or diabetes mellitus. In the present study, no patients had heart failure during the observation period.

The present study had several limitations: (1) it was a retrospective study; (2) there was no control group; (3) the sample size was insufficient to provide significant differences in some indicators; and (4) sequential liver biopsy was not performed for observing histological improvement. The preliminary findings of the present study need further verification *via* a well-controlled, prospective study with a sufficiently large sample size to confirm the efficacy of vitamin E by noninvasive scoring systems of hepatic fibrosis and Vs and differences of response according to *PNPLA3* polymorphisms.

In conclusion, vitamin E treatment for 1 year improved not only laboratory values but also the noninvasive scores of hepatic fibrosis and liver stiffness in NAFLD patients. These responses were similar between different *PNPLA3* genotypes.

**ACKNOWLEDGMENTS**

The authors thank Dr. Hiroshi Takahashi of the Division of Medical Statistics, Fujita Health University for assisting with statistical analysis.

**COMMENTS**

***Background***

Nonalcoholic fatty liver disease (NAFLD) is a common liver disease, and eventual fibrosis can lead to end-stage cirrhosis and hepatocellular carcinoma. An effective therapeutic strategy is to target reduction in oxidative stress using, for example, administration of vitamin E. Liver biopsy is still considered the gold standard for liver fibrosis assessment, despite being an invasive method and not completely risk free. Velocity of shear wave (Vs) measured by acoustic radiation force impulse (ARFI) has been reported to be a good method for assessing the stage of liver fibrosis. The single-nucleotide polymorphism rs738409 (C > G) in the patatin-like phospholipase domain containing 3 (PNPLA3) was strongly associated with increased hepatic fat levels and with hepatic inflammation in NAFLD patients. In this study, we evaluated the efficacy of vitamin E treatment for NAFLD by noninvasive methods and to assess the association between the treatment response and the PNPLA3 polymorphism.

***Research frontiers***

Few prior reports showed that vitamin E improved serum aspartate aminotransferase (AST), alanine aminotranferease (ALT), and [γ-glutamyl transpeptidase](http://xueshu.baidu.com/s?wd=%CE%B3-glutamyl%20transpeptidase%20%28%CE%B3-GTP%29&tn=SE_baiduxueshu_c1gjeupa&ie=utf-8) (γ-GTP) levels and reduced steatosis, lobular inflammation, and activity score, but did not markedly improve fibrosis scores in nonalcoholic steatohepatitis (NASH). The results of our study contribute to non-invasive evaluation of the efficacy of vitamin E treatment for NAFLD/NASH.

***Innovations and breakthroughs***

The PIVENS trial reported that serum AST, ALT, and γ-GTP levels in the vitamin E group decreased compared with the placebo group, and that vitamin E group had a reduction in steatosis, lobular inflammation, and activity score, whereas fibrosis scores did not markedly improve. The present study showed that a 1-year treatment of vitamin E improved not only laboratory values but also the noninvasive scores related to hepatic fibrosis and liver stiffness in NAFLD patients, and that the treatment responses were similar between different PNPLA3 genotypes.

***Applications***

This study suggests that liver stiffness is useful for monitoring the efficacy of vitamin E treatment for NAFLD/NASH. The patients with NAFLD/NASH can be evaluated the therapeutic effect of vitamin E using noninvasive tools without liver biopsy.

***Terminology***

ARFI: Velocity of shear wave (Vs) measured by acoustic radiation force impulse (ARFI) has been reported to be a good method for assessing the stage of liver fibrosis. *PNPLA3*: The single-nucleotide polymorphism rs738409 (C > G) in the patatin-like phospholipase domain containing 3 (*PNPLA3*) was strongly associated with increased hepatic fat levels and with hepatic inflammation in NAFLD patients

***Peer-review***

Author investigated the effect of vitamin E on NAFLD. They suggested that vitamin E treatment for 1 year reduced stiffness in NAFLD patients and the responses were similar between different *PNPLA3* genotypes. The work was logically designed and nicely described.

**REFERENCES**

1 **Williams CD**, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, Landt CL, Harrison SA. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. *Gastroenterology* 2011; **140**: 124-131 [PMID: 20858492 DOI: 10.1053/j.gastro.2010.09.038]

2 **Brunt EM**, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. *Am J Gastroenterol* 1999; **94**: 2467-2474 [PMID: 10484010 DOI: 10.1111/j.1572-0241.1999.01377.x]

3 **Bhala N**, Angulo P, van der Poorten D, Lee E, Hui JM, Saracco G, Adams LA, Charatcharoenwitthaya P, Topping JH, Bugianesi E, Day CP, George J. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. *Hepatology* 2011; **54**: 1208-1216 [PMID: 21688282 DOI: 10.1002/hep.24491]

4 **Lewis JH**, Mortensen ME, Zweig S, Fusco MJ, Medoff JR, Belder R. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. *Hepatology* 2007; **46**: 1453-1463 [PMID: 17668878 DOI: 10.1002/hep.21848]

5 **Foster T**, Budoff MJ, Saab S, Ahmadi N, Gordon C, Guerci AD. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. *Am J Gastroenterol* 2011; **106**: 71-77 [PMID: 20842109 DOI: 10.1038/ajg.2010.299]

6 **Ekstedt M**, Franzén LE, Mathiesen UL, Holmqvist M, Bodemar G, Kechagias S. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. *J Hepatol* 2007; **47**: 135-141 [PMID: 17400325 DOI: 10.1016/j.jhep.2007.02.013]

7 **Athyros VG**, Tziomalos K, Gossios TD, Griva T, Anagnostis P, Kargiotis K, Pagourelias ED, Theocharidou E, Karagiannis A, Mikhailidis DP. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. *Lancet* 2010; **376**: 1916-1922 [PMID: 21109302 DOI: 10.1016/s0140-6736(10)61272-x]

8 **Mahady SE**, Webster AC, Walker S, Sanyal A, George J. The role of thiazolidinediones in non-alcoholic steatohepatitis - a systematic review and meta analysis. *J Hepatol* 2011; **55**: 1383-1390 [PMID: 21703200 DOI: 10.1016/j.jhep.2011.03.016]

9 **Boettcher E**, Csako G, Pucino F, Wesley R, Loomba R. Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. *Aliment Pharmacol Ther* 2012; **35**: 66-75 [PMID: 22050199 DOI: 10.1111/j.1365-2036.2011.04912.x]

10 **Shyangdan D**, Clar C, Ghouri N, Henderson R, Gurung T, Preiss D, Sattar N, Fraser A, Waugh N. Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review. *Health Technol Assess* 2011; **15**: 1-110 [PMID: 22059955 DOI: 10.3310/hta15380]

11 **Chalasani N**, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. *Hepatology* 2012; **55**: 2005-2023 [PMID: 22488764 DOI: 10.1002/hep.25762]

12 **Hardwick RN**, Fisher CD, Canet MJ, Lake AD, Cherrington NJ. Diversity in antioxidant response enzymes in progressive stages of human nonalcoholic fatty liver disease. *Drug Metab Dispos* 2010; **38**: 2293-2301 [PMID: 20805291 DOI: 10.1124/dmd.110.035006]

13 **Sanyal AJ**, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. *N Engl J Med* 2010; **362**: 1675-1685 [PMID: 20427778 DOI: 10.1056/NEJMoa0907929]

14 **Rockey DC**, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. Liver biopsy. *Hepatology* 2009; **49**: 1017-1044 [PMID: 19243014 DOI: 10.1002/hep.22742]

15 **Bota S**, Herkner H, Sporea I, Salzl P, Sirli R, Neghina AM, Peck-Radosavljevic M. Meta-analysis: ARFI elastography versus transient elastography for the evaluation of liver fibrosis. *Liver Int* 2013; **33**: 1138-1147 [PMID: 23859217 DOI: 10.1111/liv.12240]

16 **Nishikawa T**, Hashimoto S, Kawabe N, Harata M, Nitta Y, Murao M, Nakano T, Mizuno Y, Shimazaki H, Kan T, Nakaoka K, Takagawa Y, Ohki M, Ichino N, Osakabe K, Yoshioka K. Factors correlating with acoustic radiation force impulse elastography in chronic hepatitis C. *World J Gastroenterol* 2014; **20**: 1289-1297 [PMID: 24574802 DOI: 10.3748/wjg.v20.i5.1289]

17 **Yoneda M**, Suzuki K, Kato S, Fujita K, Nozaki Y, Hosono K, Saito S, Nakajima A. Nonalcoholic fatty liver disease: US-based acoustic radiation force impulse elastography. *Radiology* 2010; **256**: 640-647 [PMID: 20529989 DOI: 10.1148/radiol.10091662]

18 **Palmeri ML**, Wang MH, Rouze NC, Abdelmalek MF, Guy CD, Moser B, Diehl AM, Nightingale KR. Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease. *J Hepatol* 2011; **55**: 666-672 [PMID: 21256907 DOI: 10.1016/j.jhep.2010.12.019]

19 **Fierbinteanu Braticevici C**, Sporea I, Panaitescu E, Tribus L. Value of acoustic radiation force impulse imaging elastography for non-invasive evaluation of patients with nonalcoholic fatty liver disease. *Ultrasound Med Biol* 2013; **39**: 1942-1950 [PMID: 23932277 DOI: 10.1016/j.ultrasmedbio.2013.04.019]

20 **Romeo S**, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, Boerwinkle E, Cohen JC, Hobbs HH. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. *Nat Genet* 2008; **40**: 1461-1465 [PMID: 18820647 DOI: 10.1038/ng.257]

21 **Kawaguchi T**, Sumida Y, Umemura A, Matsuo K, Takahashi M, Takamura T, Yasui K, Saibara T, Hashimoto E, Kawanaka M, Watanabe S, Kawata S, Imai Y, Kokubo M, Shima T, Park H, Tanaka H, Tajima K, Yamada R, Matsuda F. Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese. *PLoS One* 2012; **7**: e38322 [PMID: 22719876 DOI: 10.1371/journal.pone.0038322]

22 **Hotta K**, Yoneda M, Hyogo H, Ochi H, Mizusawa S, Ueno T, Chayama K, Nakajima A, Nakao K, Sekine A. Association of the rs738409 polymorphism in PNPLA3 with liver damage and the development of nonalcoholic fatty liver disease. *BMC Med Genet* 2010; **11**: 172 [PMID: 21176169 DOI: 10.1186/1471-2350-11-172]

23 **Zain SM**, Mohamed R, Mahadeva S, Cheah PL, Rampal S, Basu RC, Mohamed Z. A multi-ethnic study of a PNPLA3 gene variant and its association with disease severity in non-alcoholic fatty liver disease. *Hum Genet* 2012; **131**: 1145-1152 [PMID: 22258181 DOI: 10.1007/s00439-012-1141-y]

24 **Shah AG**, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. *Clin Gastroenterol Hepatol* 2009; **7**: 1104-1112 [PMID: 19523535 DOI: 10.1016/j.cgh.2009.05.033]

25 **Wai CT**, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. *Hepatology* 2003; **38**: 518-526 [PMID: 12883497 DOI: 10.1053/jhep.2003.50346]

26 **Promrat K**, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR, Fava JL, Wing RR. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. *Hepatology* 2010; **51**: 121-129 [PMID: 19827166 DOI: 10.1002/hep.23276]


27 **Yoshioka K**, Hashimoto S, Kawabe N. Measurement of liver stiffness as a non-invasive method for diagnosis of non-alcoholic fatty liver disease. *Hepatol Res* 2015; **45**: 142-151 [PMID: 25040931 DOI: 10.1111/hepr.12388]

28 **Sookoian S**, Castaño GO, Burgueño AL, Gianotti TF, Rosselli MS, Pirola CJ. A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity. *J Lipid Res* 2009; **50**: 2111-2116 [PMID: 19738004 DOI: 10.1194/jlr.P900013-JLR200]


29 **Sookoian S**, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. *Hepatology* 2011; **53**: 1883-1894 [PMID: 21381068 DOI: 10.1002/hep.24283]

30 **Lonn E**, Bosch J, Yusuf S, Sheridan P, Pogue J, Arnold JM, Ross C, Arnold A, Sleight P, Probstfield J, Dagenais GR. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. *JAMA* 2005; **293**: 1338-1347 [PMID: 15769967 DOI: 10.1001/jama.293.11.1338]


**P-Reviewer:** Hassanain M, Lee MK, Montalto G, Streba LAM **S-Editor:** Ji FF **L-Editor: E-Editor:**

******


**Figure 1 Characteristics of patients included in this study.** The study comprised 38 patients with nonalcoholic fatty liver disease (NAFLD) who were administered vitamin E for > 1 year. The patients were genotyped SNP rs738409 and divided into two groups by genotype (CC/CG and GG) to examine the difference in the response to vitamin E.



**Figure 2 Effects of vitamin E treatment on liver enzyme levels.** aIndicate a difference when the results are compared with baseline values (*P* < 0.05). A:Evolution of AST during the study period. Serum AST levels in all patients decreased from baseline to 6 and 12 mo (*P* < 0.001 and *P* < 0.001, respectively). Serum AST levels in the CC/CG group decreased from baseline to 6 and 12 mo (*P* = 0.004 and *P* < 0.001, respectively). Serum AST levels in the GG group also decreased from baseline to 6 and 12 mo (*P* = 0.045 and *P* = 0.011, respectively); B: Evolution of ALT during the study period. Serum ALT levels in all patients decreased from baseline to 6 and 12 mo (*P* < 0.001 and *P* < 0.001, respectively). Serum ALT levels in the CC/CG group decreased from baseline to 6 and 12 mo (*P* = 0.022 and *P* < 0.001, respectively). Serum ALT levels in the GG group also decreased from baseline to 6 and 12 mo (*P* = 0.004 and *P* < 0.001, respectively); C: Evolution of γ-GTP during the study period. Serum γ-GTP levels in all patients decreased from baseline to 6 and 12 mo (*P* = 0.019 and *P* < 0.001, respectively). Serum γ-GTP levels in the CC/CG group decreased from baseline to 6 and 12 mo (*P* = 0.047 and *P* = 0.003, respectively). Those in the GG group decreased from baseline to 12 mo (*P* = 0.005). AST: Aspartate aminotransferase; ALT: Alanine aminotranferease; γ-GTP: [γ-glutamyl transpeptidase](http://xueshu.baidu.com/s?wd=%CE%B3-glutamyl%20transpeptidase%20%28%CE%B3-GTP%29&tn=SE_baiduxueshu_c1gjeupa&ie=utf-8).



**Figure 3 Effects of vitamin E treatment on results of noninvasive scoring systems of hepatic fibrosis.** aIndicate a difference compared with baseline values (*P* < 0.05). A: Evolution of FIB-4 index during the study period. FIB-4 index in all patients decreased from baseline to 6 and 12 mo (*P* = 0.015 and *P* = 0.035, respectively). The FIB-4 index in the CC/CG group also decreased from baseline to 6 and 12 mo (*P* = 0.014 and *P* = 0.017, respectively); B: Evolution of APRI during the study period. APRI in all patients decreased from baseline to 6 and 12 mo (*P* < 0.001 and *P* < 0.001, respectively). APRI in the CC/CG group decreased from baseline to 6 and 12 mo (*P* = 0.004 and *P* < 0.001, respectively). APRI in the GG group also decreased from baseline to 6 and 12 mo (*P* = 0.028 and *P* = 0.036, respectively). FIB-4: Fibrosis-4; APRI: Aminotransferase-to-platelet index.



**Figure 4 Evolution of velocity of shear wave during the study period.** aIndicate a difference compared with baseline values (*P* < 0.05). Velocity of shear wave (Vs) in all patients decreased from baseline to 12 mo (*P* = 0.005). Vs in the GG group also decreased from baseline to 12 mo (*P* = 0.029), and that in the CC/CG group also tended to decrease (*P* = 0.083).

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Table 1 Clinical characteristics and laboratory values of the patients at baseline** | | | | |
|  | All patients | *PNPLA3* Genotype | | *P* value *PNPLA3* CC/CG *vs* GG |
|  |  | *CC/CG* | *GG* |
| No. of subjects | 38 | 19 | 19 |
| Sex (male/female) | 10/28 | 6/13 | 4/15 | 0.461 |
| Age (yr) | 62.0 ± 11.6 | 58.4 ± 11.9 | 65.6 ± 10.1 | 0.061 |
| Height (cm) | 156.6 ± 9.9 | 158.7 ± 11.3 | 154.4 ± 7.6 | 0.226 |
| Body weight (kg) | 68.2 ± 14.9 | 69.7 ± 16.1 | 66.7 ± 13.5 | 0.685 |
| Body mass index (kg/m2) | 27.9 ± 4.7 | 27.7 ± 4.0 | 28.0 ± 5.3 | 0.988 |
| Classification of NAFLD |  |  |  |  |
| Fatty liver confirmed by an imaging examination | 23 | 13 | 10 | 0.347 |
| NASH confirmed by a liver biopsy | 9 | 5 | 4 |
| Nonviral liver cirrhosis diagnosed clinically | 5 | 1 | 4 |
| Burn-out NASH confirmed by a liver biopsy | 1 | 0 | 1 |
| Child–Pugh grade of cirrhotic patients (A/B/C) | 4/2/0 | 1/0/0 | 3/2/0 | 0.439 |
| Concurrent diabetes mellitus (+/−) | 15/23 | 5/14 | 10/9 | 0.097 |
| Concurrent hepatocellular cancer (+/−) | 0/38 | 0/19 | 0/19 | - |
| Dosage of vitamin E (150 mg/300 mg/600 mg) | 2/4/32 | 2/1/16 | 0/3/16 | 0.223 |
| Concurrent medication |  |  |  |  |
| Pioglitazone | 3 | 2 | 1 | 0.547 |
| Metformin | 2 | 2 | 0 | 0.146 |
| Ursodeoxycholic acid | 27 | 14 | 13 | 0.721 |
| HMG-CoA reductase inhibitor | 13 | 6 | 7 | 0.732 |
| Ezetimibe | 7 | 6 | 1 | 0.036a |
| Angiotensin receptor 2 antagonist | 9 | 6 | 3 | 0.252 |
| Serum biochemical tests |  |  |  |  |
| Platelet count (×104/μL) | 16.7 ± 7.5 | 19.3 ± 7.1 | 14.1 ± 6.9 | 0.046a |
| Prothrombin activity (%) | 98.5 ± 18.7 | 104.2 ± 17.6 | 93.2 ± 18.2 | 0.061 |
| Hemoglobin A1c (%) | 6.38 ± 1.06 | 6.26 ± 0.97 | 6.49 ± 1.14 | 0.394 |
| Total protein (g/dL) | 7.42 ± 0.52 | 7.47 ± 0.49 | 7.36 ± 0.54 | 0.435 |
| Serum albumin (g/dL) | 4.27 ± 0.39 | 4.41 ± 0.36 | 4.14 ± 0.37 | 0.032a |
| Total bilirubin (mg/dL) | 0.98 ± 0.50 | 0.84 ± 0.29 | 1.11 ± 0.61 | 0.172 |
| Aspartate aminotransferase (IU/L) | 61.1 ± 29.9 | 58.2 ± 32.2 | 64.1 ± 27.2 | 0.191 |
| Alanine aminotransferase (IU/L) | 68.5 ± 41.2 | 69.9 ± 36.0 | 67.1 ± 45.7 | 0.385 |
| Alkaline phosphatase (IU/L) | 312 ± 108 | 270 ± 85 | 355 ± 112 | 0.032a |
| γ-Glutamyltransferase (IU/L) | 87.4 ± 70.0 | 72.6 ± 59.1 | 101.5 ± 76.4 | 0.142 |
| Total cholesterol (mg/dL) | 185 ± 37 | 194 ± 43 | 176 ± 28 | 0.172 |
| Triglycerides (mg/dL) | 151 ± 85 | 147 ± 99 | 156 ± 64 | 0.351 |
| Cholinesterase (IU/L) | 333 ± 124 | 353 ± 91 | 313 ± 147 | 0.172 |
| Scoring systems of hepatic fibrosis |  |  |  |  |
| FIB-4 index | 3.80 ± 2.78 | 2.61 ± 1.74 | 4.98 ± 3.10 | 0.006a |
| APRI | 1.50 ± 0.94 | 1.17 ± 0.75 | 1.84 ± 0.98 | 0.014a |
| Velocity of shear wave (m/s) | 2.20 ± 0.91 | 1.81 ± 0.76 | 2.56 ± 0.89 | 0.010a |

Data are presented as number of patients or means ± SD. Statistical analysis was performed by χ2 test or Mann–Whitney *U* test. a*P* < 0.05. *PNPLA3:* Patatin-like phospholipase domain containing 3; NAFLD: Nonalcoholic fatty liver disease; NASH: Nonalcoholic steatohepatitis; APRI: Aspartate aminotransferase-to-platelet ratio index.